BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 25105871)

  • 21. The presence of circulating tumor cells (CTCs) correlates with lymph node metastasis in nonresectable squamous cell carcinoma of the head and neck region (SCCHN).
    Hristozova T; Konschak R; Stromberger C; Fusi A; Liu Z; Weichert W; Stenzinger A; Budach V; Keilholz U; Tinhofer I
    Ann Oncol; 2011 Aug; 22(8):1878-85. PubMed ID: 21525401
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic value of circulating tumor cells in patients with squamous cell carcinoma of the head and neck: a systematic review and meta-analysis.
    Wang Z; Cui K; Xue Y; Tong F; Li S
    Med Oncol; 2015 May; 32(5):164. PubMed ID: 25895596
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients.
    Wallwiener M; Hartkopf AD; Riethdorf S; Nees J; Sprick MR; Schönfisch B; Taran FA; Heil J; Sohn C; Pantel K; Trumpp A; Schneeweiss A
    BMC Cancer; 2015 May; 15():403. PubMed ID: 25972110
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic and clinicopathological significance of circulating tumor cells detected by RT-PCR in non-metastatic colorectal cancer: a meta-analysis and systematic review.
    Yang C; Zou K; Zheng L; Xiong B
    BMC Cancer; 2017 Nov; 17(1):725. PubMed ID: 29115932
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A simple multicolor flow cytometry protocol for detection and molecular characterization of circulating tumor cells in epithelial cancers.
    Hristozova T; Konschak R; Budach V; Tinhofer I
    Cytometry A; 2012 Jun; 81(6):489-95. PubMed ID: 22438318
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circulating Tumor Cells Correlate With Prognosis in Head and Neck Squamous Cell Carcinoma.
    Zhou S; Wang L; Zhang W; Liu F; Zhang Y; Jiang B; Wang J; Yuan H
    Technol Cancer Res Treat; 2021; 20():1533033821990037. PubMed ID: 33641530
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment.
    Giuliano M; Giordano A; Jackson S; Hess KR; De Giorgi U; Mego M; Handy BC; Ueno NT; Alvarez RH; De Laurentiis M; De Placido S; Valero V; Hortobagyi GN; Reuben JM; Cristofanilli M
    Breast Cancer Res; 2011 Jun; 13(3):R67. PubMed ID: 21699723
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts.
    Lorente D; Olmos D; Mateo J; Dolling D; Bianchini D; Seed G; Flohr P; Crespo M; Figueiredo I; Miranda S; Scher HI; Terstappen LWMM; de Bono JS
    Ann Oncol; 2018 Jul; 29(7):1554-1560. PubMed ID: 29741566
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical significance of tumor cells in the peripheral blood of patients with esophageal squamous cell carcinoma.
    Han L; Li YJ; Zhang WD; Song PP; Li H; Li S
    Medicine (Baltimore); 2019 Feb; 98(6):e13921. PubMed ID: 30732126
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Circulating tumor cells as an independent prognostic factor in advanced colorectal cancer: a retrospective study in 121 patients.
    Wang L; Zhou S; Zhang W; Wang J; Wang M; Hu X; Liu F; Zhang Y; Jiang B; Yuan H
    Int J Colorectal Dis; 2019 Apr; 34(4):589-597. PubMed ID: 30627849
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer.
    Müller V; Riethdorf S; Rack B; Janni W; Fasching PA; Solomayer E; Aktas B; Kasimir-Bauer S; Zeitz J; Pantel K; Fehm T;
    Breast Cancer Res; 2011 Jul; 13(4):R71. PubMed ID: 21745383
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients.
    Zhang S; Li L; Wang T; Bian L; Hu H; Xu C; Liu B; Liu Y; Cristofanilli M; Jiang Z
    BMC Cancer; 2016 Jul; 16():526. PubMed ID: 27456503
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Circulating tumour cells in metastatic head and neck cancers.
    Kulasinghe A; Perry C; Jovanovic L; Nelson C; Punyadeera C
    Int J Cancer; 2015 Jun; 136(11):2515-23. PubMed ID: 25111594
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Circulating tumor cells in newly diagnosed inflammatory breast cancer.
    Mego M; Giordano A; De Giorgi U; Masuda H; Hsu L; Giuliano M; Fouad TM; Dawood S; Ueno NT; Valero V; Andreopoulou E; Alvarez RH; Woodward WA; Hortobagyi GN; Cristofanilli M; Reuben JM
    Breast Cancer Res; 2015 Jan; 17(1):2. PubMed ID: 25572591
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
    Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
    Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical significance of circulating tumor cells in patients with locally advanced head and neck squamous cell carcinoma.
    Liu K; Chen N; Wei J; Ma L; Yang S; Zhang X
    Oncol Rep; 2020 May; 43(5):1525-1535. PubMed ID: 32323844
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HER2-positive circulating tumor cells in breast cancer.
    Ignatiadis M; Rothé F; Chaboteaux C; Durbecq V; Rouas G; Criscitiello C; Metallo J; Kheddoumi N; Singhal SK; Michiels S; Veys I; Rossari J; Larsimont D; Carly B; Pestrin M; Bessi S; Buxant F; Liebens F; Piccart M; Sotiriou C
    PLoS One; 2011 Jan; 6(1):e15624. PubMed ID: 21264346
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Meta-analysis of the prognostic value of circulating tumor cells detected with the CellSearch System in colorectal cancer.
    Huang X; Gao P; Song Y; Sun J; Chen X; Zhao J; Xu H; Wang Z
    BMC Cancer; 2015 Mar; 15():202. PubMed ID: 25880692
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Circulating tumor cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer.
    De Laere B; Oeyen S; Van Oyen P; Ghysel C; Ampe J; Ost P; Demey W; Hoekx L; Schrijvers D; Brouwers B; Lybaert W; Everaert E; Van Kerckhove P; De Maeseneer D; Strijbos M; Bols A; Fransis K; Beije N; de Kruijff I; van Dam V; Brouwer A; van Dam PJ; Van den Eynden G; Rutten A; Sleijfer S; Vandebroek J; Van Laere S; Dirix L
    Prostate; 2018 May; 78(6):435-445. PubMed ID: 29431193
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic Threshold for Circulating Tumor Cells in Patients With Pancreatic and Midgut Neuroendocrine Tumors.
    Mandair D; Khan MS; Lopes A; Furtado O'Mahony L; Ensell L; Lowe H; Hartley JA; Toumpanakis C; Caplin M; Meyer T
    J Clin Endocrinol Metab; 2021 Mar; 106(3):872-882. PubMed ID: 33180939
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.